文献速递类风湿关节炎

类风湿关节炎患者大手术前停用英夫利西单抗与术后感染风险

Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该回顾性队列研究利用2007至2015年美国Medicare索赔数据,分析712例冠状动脉旁路移植术、244例血管手术和862例肠切除的类风湿关节炎患者,探讨术前英夫利西单抗输注时机与术后30天感染及死亡的关系。结果显示,最后一次英夫利西单抗给药至手术的时间与术后感染或死亡率无关联,未发现更接近手术使用英夫利西单抗会增加感染风险的亚组。

要点

  • 术前英夫利西单抗输注时机与术后30天感染或死亡风险无关联。
  • 各手术队列术后肺炎发生率7.4-11.9%,尿路感染9.0-15.2%。
  • 未发现更接近手术使用英夫利西单抗增加感染风险的亚组。

核心结论

  • 在老年类风湿关节炎患者中,大手术术后感染和死亡风险与术前英夫利西单抗输注时机无关。

研究设计与样本

  • 基于2007至2015年美国Medicare索赔数据的群体性回顾性队列研究。
  • 纳入术前90天内接受英夫利西单抗治疗并接受冠状动脉旁路移植术、主动脉或血管手术或肠切除的类风湿关节炎患者。
  • 分析术前输注时机与术后30天感染及死亡的关系,并调整术后感染或死亡的预测概率、人口学特征、甲氨蝶呤使用、术后输血和医院规模。

主要发现

  • 研究包括712例冠状动脉旁路移植术、244例血管手术和862例肠切除患者。
  • 术后肺炎发生率7.4-11.9%,尿路感染9.0-15.2%,手术部位感染3.2-18.9%,脓毒症4.2-9.6%,死亡3.5-7.0%。
  • 在任何手术队列中,最后一次英夫利西单抗给药至手术的时间与术后感染或死亡风险均无关联。
  • 未发现更接近手术使用英夫利西单抗会增加感染风险的亚组。

临床怎么用

  • 对于接受大手术的老年类风湿关节炎患者,术前英夫利西单抗的输注时机可能无需作为术后感染风险的独立考量因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Withholding TNF inhibitors (TNFI) before surgery has been recommended due to concern for post-operative infection. We examined the risks of post-operative infections and mortality in patients with RA in relation to the pre-operative timing of infliximab infusion. METHODS: In this population-based retrospective cohort study, we used US Medicare claims data from 2007 to 2015 to identify patients with RA who underwent coronary artery bypass grafting (CABG), aortic or vascular surgery, or bowel resection, and who were treated with infliximab in the 90 days prior to surgery. We examined associations between the timing of infusion and infections and mortality in the 30 days after surgery. We adjusted for the predicted probability of post-operative infection or death, demographic characteristics, use of MTX, post-operative blood transfusion and hospital volume. RESULTS: We studied 712 patients with CABG, 244 patients with vascular surgery and 862 patients with bowel resections. Post-operative pneumonia occurred in 7.4-11.9%, urinary tract infection in 9.0-15.2%, surgical site infection in 3.2-18.9%, sepsis in 4.2-9.6% and death in 3.5-7.0% among surgery cohorts. There was no association between the time from last infliximab dose to surgery and the risk of post-operative infection or mortality in any surgical cohort. No subgroups were identified that had an increased risk of infection with more proximate use of infliximab. CONCLUSION: Among elderly patients with RA, risks of infection and mortality after major surgery were not related to the pre-operative timing of infliximab infusion.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Ward MM, Dasgupta A. Pre-operative withholding of infliximab and the risk of infections after major surgery in patients with rheumatoid arthritis. Rheumatology (Oxford). 2020. PMID: 32710102. doi:10.1093/rheumatology/keaa291

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。